Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing

Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular heterogeneity, there is a need to identify genetic alt...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Inês Costa, Joana Reis, Sara Meireles, Maria João Ribeiro, Isabel Augusto, Miguel Barbosa
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SMC MEDIA SRL 2022-05-01
Edice:	European Journal of Case Reports in Internal Medicine
Témata:	metastatic prostate cancer brca2 germline mutation parp inhibitor olaparib carboplatin brca2-mutated metastatic castration-resistant prostate cancer
On-line přístup:	https://www.ejcrim.com/index.php/EJCRIM/article/view/3331
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!